Dr. Mikael Dolsten: We continue to be enthusiastic about gene therapy in DMD. I think we have actually published the strongest data on the two drugs with efficacy as well as a lot of biomarkers from our Phase 1 across a much broader age group than anyone else. And I can’t comment when possibly someone else will get it registered. But, we expect data readouts within possibly less than a year. And we think that this could be a very important drug. And we will have randomized data, which is not the case for any other application currently to have at that size and scope.
Dr. Albert Bourla: As regards the assumptions of our COVID protection vaccines, for example, we are dropping the numbers. So for example, 31% of people receiving a vaccine, that was the actual in €˜22. We are going to €˜24. Then you are reaching a level of really people that they are really committed to the idea of getting vaccinations and they are looked by physicians that don’t really believe in the vaccination, the value of vaccinations. We are also dropping the number of doses there. So, we’ll go to 1.3. And then eventually, as the years progress, the number of doses that people will receive is small. Keep in mind that to get numbers like 1.2, you need a very, very small percent of population 2 doses, so that you can achieve something like that.
Maybe 5% of the population to get a second dose, and then you will go to these numbers, as you will see, if you include also primary doses and children. So, we believe the assumptions are very reasonable with the expectations that COVID will remain as it is right now, so nothing more severe and nothing that will make it less disappearing and we take into consideration that the compliance with the recommendation of the health authorities also because of the fact, will be less. Clearly, pivotal moment will be the introduction of combination vaccines because the convenience of something like that and the fact that people are presenting themselves to receive flu vaccines, given that a combo vaccine would be in the same injection and will cost zero co-pay, likely will become the choice of many to get this full coverage.
So, we have quite confidence on these assumptions. And of course, there are only assumptions. We need to wait and see. The other thing, it is — on the Europe, you asked a few questions. I know that there are rumors, but I don’t think that it is appropriate for us to make any comments while we are in negotiation with our partners in Commission and with the member states. So, we only said that we factor on part of the deliveries in this year instead of all the deliveries because we are in the middle of negotiations, but we can’t make other comments. Next question, please.
Operator: Our next question will come from Trung Huynh with Credit Suisse.
Trung Huynh: Hi, guys. Good morning. It’s Trung Huynh from Credit Suisse. I have a quick clarification on COVID and then my question. So just on the clarification in those long-term COVID vaccine and Pax slides. Do you expect any U.S. government sales in €˜24 and €˜26? It just looks like commercial sales on your slides. So, does that mean Medicaid, Medicare populations are bought at a commercial price? And can you comment on the margin change for the vaccine and Pax as you step up to that commercial price? And secondly, just following on from the base business question from Steve, we saw lower revenues ex U.S. for some important base business drugs. So, Eliquis was down 19% ex U.S., IBRANCE minus 22% ex U.S., Prevnar, there was also a decline there.
You’ve noted some product-product related issues. But are you seeing anything more broadly in the U.S., which is making it for a more difficult environment? And going forward, should we expect more normal levels ex U.S. for these products?
